Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you.
Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you.
• Keep this leaflet. You may need to read it again.
• Ask your doctor, pharmacist or nurse if you need more information or advice.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

Composition
Active constituents
1 g of Emla Cream contains lidocaine 25 mg, prilocaine 25 mg.

Excipient with known effect:
EMLA Cream contains macrogol glycerol hydroxystearate which can cause skin reactions.
For excipients see List of excipients.

Pharmaceutical form:
Cream.
Emla is an oil/water emulsion in which the oil phase consists of a eutectic mixture of lidocaine and prilocaine in the ratio 1:1.

Therapeutic indications
• Surface anaesthesia of the skin in connection with needle insertion and for superficial surgical procedures.
• Surface anaesthesia of leg ulcers prior to cleaning and superficial surgical procedures, for example removal of fibrin, pus and necroses.
• Surface anaesthesia of the genital mucosa.

Posology and method of administration
Adults
Intact skin

<table>
<thead>
<tr>
<th></th>
<th>Dose and administration</th>
<th>Application time</th>
</tr>
</thead>
<tbody>
<tr>
<td>for needle insertion</td>
<td>½ tube (approx. 2 g) per 10 cm². A thick layer of cream is applied to the skin and covered with an occlusive dressing</td>
<td>1 hour; maximum 5 hours</td>
</tr>
<tr>
<td>e.g. insertion of intravenous lines, taking blood samples</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for minor superficial surgical procedures, e.g. curettage of the lesions caused by Mollusca contagiosa</td>
<td>1.5-2 g per 10 cm². A thick layer of cream is applied to the skin and covered with an occlusive dressing</td>
<td>1 hour; maximum 5 hours</td>
</tr>
<tr>
<td>for more extensive superficial surgical procedures, e.g. split skin grafting</td>
<td>1.5-2 g per 10 cm². A thick layer of cream is applied to the skin and covered with an occlusive dressing</td>
<td>2 hours; maximum 5 hours</td>
</tr>
<tr>
<td>On large areas of newly shaven skin (in outpatient care)</td>
<td>Maximum recommended dose: 60 g. Maximum recommended treatment area: 600 cm²</td>
<td>1 hour; maximum 5 hours</td>
</tr>
</tbody>
</table>
**Leg ulcers**

For cleaning of leg ulcers: approx. 1-2 g per 10 cm². The cream is applied in a thick layer to the surface of the ulcer, but not more than 10 g per treatment procedure. Cover the surface of the ulcer with an occlusive dressing. An opened tube is intended for a single use, and any remaining cream must therefore be discarded after each treatment procedure.

**Application time:** at least 30 minutes.

For leg ulcers with tissue that is particularly difficult to penetrate the application time may be extended to 60 minutes.

Cleaning of the ulcer should begin within 10 minutes after the cream has been removed.

Emla has been used for up to 15 treatment procedures over a period of 1-2 months without a decline in effect or an increase in the number of local reactions.

**Genital use**

**Skin**

Use prior to injection of local anaesthetics:

**Men:**
1 g per 10 cm². A thick layer of cream is applied to the skin.

**Application time:** 15 minutes.

**Women:**
1-2 g per 10 cm². A thick layer of cream is applied to the skin.

**Application time:** 60 minutes.

**Genital mucosa**

For removal of condyloma or prior to injection of local anaesthetics: approx. 5-10 g, depending on the area to be treated.

The whole surface, including the mucosal folds, must be covered. Occlusion is not necessary.

**Application time:** 5-10 minutes. The surgery must be begun immediately after removal of the cream.

**Children**

For needle insertion, curettage of the lesions caused by mollusca contagiosa and other minor surgical procedures: 1 g per 10 cm².

A thick layer of cream is applied to the skin and covered with an occlusive dressing. The dose should not exceed 1 gram per 10 cm² and must be adjusted according to the application area.

<table>
<thead>
<tr>
<th>Age</th>
<th>Application area</th>
<th>Application time</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3 months</td>
<td>maximum 10 cm² (total of 1 g)</td>
<td>1 hour (note: not longer)</td>
</tr>
<tr>
<td></td>
<td>(maximum daily dose)</td>
<td></td>
</tr>
<tr>
<td>3-12 months</td>
<td>maximum 20 cm² (total of 2 g)</td>
<td>1 hour</td>
</tr>
<tr>
<td>1-6 years</td>
<td>maximum 100 cm² (total of 10 g)</td>
<td>1 hour; maximum 5 hours¹</td>
</tr>
<tr>
<td>6-12 years</td>
<td>maximum 200 cm² (total of 20 g)</td>
<td>1 hour; maximum 5 hours¹</td>
</tr>
</tbody>
</table>

¹After a longer application time, the anaesthesia decreases.

Children with atopic dermatitis: reduce application time to 30 minutes.

**Contraindications**

Known hypersensitivity to local anaesthetics of the amide type or to any of the excipients.

Emla must not be used on premature infants (born before week 37 of pregnancy).

**Special warnings and precautions for use**

Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methaemoglobinemia are more susceptible to drug-induced methaemoglobinemia.

Studies have been unable to demonstrate the efficacy of Emla for heel lancing in neonates.

Caution when using near the eyes, as Emla may cause eye irritation. Also the loss of protective reflexes may allow corneal irritation and potential abrasion. If eye contact occurs, immediately rinse the eye in water or sodium chloride solution and protect until sensation returns.

Caution when using on areas on skin with atopic dermatitis; the application time should be reduced (15-30 minutes). Application times longer than 30 minutes in patients with atopic dermatitis may result in an increased incidence of local vascular reactions, particularly application site redness and in some cases petechia and purpura (see section Undesirable effects).

Prior to removal of mollusca contagiosa in children with atopic dermatitis it is recommended to apply the cream for 30 minutes.
In children under 3 months, safety and efficacy have only been studied with application of a single dose. In these children, a transient increase in methaemoglobin levels is often seen for up to 13 hours after Emla has been applied. However, the increases that have been observed are probably of no clinical significance.

Patients treated with anti-arrhythmic drugs class III (e.g. amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive.

Emla should not be used on damaged tympanic membrane or in other situations where penetration into the middle ear may occur.

Emla should not be applied to open wounds.

Emla should not be used on the genital mucosa in children on account of incomplete data of absorption.

Lidocaine and prilocaine have bacteriocidal and antiviral properties in concentrations above 0.5-2%. For this reason the results of intracutaneous injections of live vaccines (e.g. BCG) should be monitored.

Until further clinical experience is available, Emla should not be used for children aged 0-12 months during concomitant treatment with methaemoglobin-inducing drugs (see also Overdose).

EMLA cream contains macrogol glycerol hydroxystearate which can cause skin reactions.

**Interactions**

Emla can potentiate the formation of methaemoglobin in patients who are being treated with certain methaemoglobin-inducing preparations (e.g. sulpha preparations).

With high doses of Emla, the risk of additive systemic effects should be taken into account in patients who are given local anaesthetics or preparations that are structurally similar to local anaesthetics, e.g. tocainide.

Specific interaction studies with lidocaine/prilocaine and anti-arrhythmic drugs class III (e.g. amiodarone) have not been performed, but caution is advised (See also Special Warnings and precautions for use).

Medicinal products that reduce the clearance of lidocaine (e.g. cimetidine or beta-blockers) may cause potentially toxic plasma levels when lidocaine is given in repeated high doses for prolonged periods of time.

Such interactions are not clinically significant in short-term treatment with lidocaine at recommended doses.

**Pregnancy and lactation**

**Pregnancy**

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. In both animal and humans, lidocaine and prilocaine cross the placental barrier and may be absorbed by the foetal tissue. It is reasonable to assume that lidocaine and prilocaine have been used in a large number of pregnant women and women of childbearing potential. No specific disturbances to the reproductive process have so far been reported, e.g. an increased incidence of malformations or other directly or indirectly harmful effects on the foetus. However, caution should be exercised when used in pregnant women.

**Lactation**

Lidocaine and prilocaine pass into the breast milk, but the risk of an effect on the child appears unlikely with therapeutic doses.

**Effects on ability to drive and use machines**

Reaction capacity is not affected by treatment with Emla.
Undesirable effects

Adverse events with local anaesthetics in the actual sense of the term occur in fewer than 1/1000 patients treated.

<table>
<thead>
<tr>
<th>Skin</th>
<th>Common (≥1/100, &lt;1/10)</th>
<th>Transient local reactions at the application site, such as paleness, redness, oedema.1,2,3. An initial and usually mild sensation of burning, itching or warmth at the application site.3,2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Less common (≥1/1000, &lt;1/100)</td>
<td>Initially a slight burning sensation, itching (at the application site).1 Local paresthesia on the application site, e.g. a tingling sensation.2 Skin irritation on the application site.3</td>
</tr>
<tr>
<td>General disorders and Administration site conditions</td>
<td>Rare (≥1/10000, &lt;1/1000)</td>
<td>Allergic reactions, in the most severe cases anaphylactic shock.1,2,3 Methaemoglobinaemia1 (See Interactions and Overdose). Skin reactions at the application site, such as purpura or petechiae, especially following longer application times in children with atopic dermatitis or mollusca contagiosa.1 In cases of accidental contact with the eye, corneal irritation may occur.1</td>
</tr>
</tbody>
</table>

1 Intact skin  
2 Genital mucosa  
3 Leg Ulcers

Overdose

Systemic toxicity is very unlikely with normal use of Emla. In the event of toxicity, the symptoms are expected to be similar to those seen after local anaesthesia treatment, i.e. excitatory CNS symptoms and in severe cases CNS depression and myocardial depression.

Rare cases of clinically significant methaemoglobinaemia have been reported (See Undesirable effects). Prilocaine in high doses can increase the methaemoglobin level.

Topical administration of 125 mg prilocaine for 5 hours caused moderate methaemoglobinaemia in a 3-months-old child. Topical administration of 8.6-17.2 mg/kg lidocaine caused very serious intoxication in infants.

Severe neurological symptoms (convulsions, CNS depression) require symptomatic treatment such as assisted ventilation and anticonvulsant therapy.

In the event of methaemoglobinaemia methyl thionine is the antidote. On account of a slow systemic absorption, a patient with symptoms of toxicity should be kept under observation for several hours following any treatment of these symptoms.

Pharmacodynamic properties

Pharmacotherapeutic group: Local anaesthetics of the amide type  
ATC code: N01B B20

Emla cream contains lidocaine and prilocaine, which are local anaesthetics of the amide type. On penetration into the epidermis and dermis, these substances produce dermal anaesthesia. The degree of anaesthesia depends on application time and dose.

Intact skin

With an application time of 1-2 hours the effect lasts for approximately two hours after the occlusive dressing has been removed.

In clinical studies of Emla on intact skin, no differences in safety or efficacy (including anaesthetic onset time) were observed between geriatric patients (aged 65-96 years) and younger patients.

The superficial vascular bed is affected by Emla, and this can cause transient paleness or redness. These reactions appear to occur more rapidly in atopic dermatitis, after only 30-60 minutes, indicating more rapid absorption through the skin (see also Special warnings and precautions for use).
A study in healthy volunteers with intact skin shows that in 90% the anaesthesia is sufficient for use of biopsy punch (4 mm in diameter) to an insertion depth of 2 mm, following 60 minutes application time and to a depth of 3 mm following 120 minutes application time. The effectiveness of Emla is independent of the colour of the skin/pigmentation of the skin (skin types I-IV).

Emla can be used prior to vaccination with subcutaneous or intramuscular vaccine. For intracutaneous vaccination with live vaccine e.g. BCG, see Special warnings and precautions for use.

**Genital mucosa**

The time to onset of the necessary anaesthesia is shorter, as absorption is more rapid than with application to intact skin. Following 5-10 minutes application of Emla to the genital mucosa in women, the anaesthetic effect against argon laser induced pain lasted for 15-20 minutes (with an interindividual variation from 5-45 minutes).

**Leg ulcers**

No negative effect on ulcer healing or bacterial flora has been observed. When cleaning leg ulcers Emla has analgesic effect for up to 4 hours after application.

**Pharmacokinetic properties**

The systemic absorption of Emla depends on the amount of cream, the application time, the thickness of the skin (which varies on different surfaces of the body) and the condition of the skin in other respects such as skin diseases (e.g. absorption increases in atopic dermatitis, see Special warnings and precautions for use) and shaving. When used on leg ulcers, the characteristics of the leg ulcer can affect absorption, e.g. absorption increases with increased size of the leg ulcer.

**Intact skin**

After application of 60 g Emla cream per 400 cm² (1.5 g per 10 cm²) for three hours to intact skin (the thigh) in adults, systemic absorption was measured as 3% for lidocaine and 5% for prilocaine. Absorption takes place slowly. With the above mentioned dose, peak plasma concentrations for lidocaine (mean 0.12 μg/ml) and prilocaine (mean 0.07 μg/ml) were reached within approximately 4 hours after application. Only at levels of 5-10 μg/ml are there risks of toxic symptoms. In this case, shaving of the skin took place 8-12 hours before application of the cream.

Plasma levels of lidocaine and prilocaine in both geriatric and nongeriatric patients following application of Emla to intact skin are very low and well below potentially toxic levels.

**Leg ulcers**

After application to leg ulcers of 5-10g Emla for 30 minutes peak plasma levels of lidocaine and prilocaine were reached after approximately 1-2.5 hours (for lidocaine within the range 0.05-0.84 μg/ml and for prilocaine 0.02-0.08 μg/ml).

Following repeated application of Emla to leg ulcers there was no apparent accumulation in plasma of lidocaine, prilocaine or their metabolites. 2-10 g Emla was applied for 30-60 minutes to a maximal surface of 62 cm², in total 15 times during a period of one month, 3-7 sessions a week.

**Genital mucosa**

After application of 10 g Emla cream to vaginal mucosa for 10 minutes, peak plasma concentrations were measured after approximately 35 minutes (mean values: lidocaine 0.18 μg/ml, prilocaine 0.15 μg/ml).

**List of excipients**

Carbomer, macrogol glycerol hydroxystearate. Sodium hydroxide to pH 8.7-9.7, water.

**Shelf life**

Please refer to expiry date on the outer carton.

**Special precautions for storage**

Do not store above 30 °C. Do not freeze.

**Pack size**

Please refer to outer carton for pack size

Instructions for use and handling Information for the user and instructions for use are contained in every pack.

Use the tube cap in order to perforate the membrane covering the tip of the tube.

**Date of revision of the text**

February 2018

Trademarks are owned by or licensed to the Aspen group of companies

© 2017 Aspen group of companies or its licensor. All rights reserved.

Manufactured by Recipharm Karlskoga AB, Björkbornsvägen 5, SE-691 33 Karlskoga, Sweden for Aspen .